Barclays Begins Coverage on Elanco Animal Health (NYSE:ELAN)

Research analysts at Barclays assumed coverage on shares of Elanco Animal Health (NYSE:ELAN) in a research report issued on Tuesday. The firm set an “overweight” rating and a $30.00 price target on the stock. Barclays‘s price objective indicates a potential upside of 38.34% from the company’s current price.

A number of other research firms have also issued reports on ELAN. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Piper Sandler raised their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, August 11th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. UBS Group lifted their target price on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Stifel Nicolaus lifted their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.78.

Elanco Animal Health Price Performance

NYSE ELAN opened at $21.69 on Tuesday. The stock has a market capitalization of $10.77 billion, a P/E ratio of 361.48, a P/E/G ratio of 2.97 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The business’s fifty day moving average is $21.69 and its two-hundred day moving average is $17.87. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $23.70.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.Elanco Animal Health’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Several large investors have recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in shares of Elanco Animal Health during the 1st quarter worth approximately $115,212,000. UBS Group AG raised its stake in shares of Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after purchasing an additional 5,961,457 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Elanco Animal Health by 14.3% in the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock worth $214,875,000 after purchasing an additional 2,563,740 shares during the period. Jennison Associates LLC boosted its stake in Elanco Animal Health by 322.0% during the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after buying an additional 2,468,122 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.